A Pan-Cancer Analysis Indicates the Prognostic Significance and Immunological Function of V-Set Domain Containing T-Cell Activation Inhibitor 1

The immune costimulatory protein V-set domain containing T cell activation inhibitor 1 is a key molecule in the B7 family developing advanced growth in multiple cancers as a suppressive regulatory factor during T cell immunoreaction. For the purpose of confirming the importance of prognosis and ascertaining the effects on tumor immunity of V-set domain containing T cell activation inhibitor 1 gene expression across diverse cancers. The design utilized a wide range of tools involved in bioinformatics from the available public database to integrally identify the association between V-set domain containing T cell activation inhibitor 1 and prognosis, clinic pathological features, tumor mutational burden, microsatellite instability, methyl transferase, mismatch repair, immune cell permeation among different tumors, chemotherapy drug sensitivities, and try to comprehensively probe potentially carcinogenic of V-set domain containing T cell activation inhibitor 1. The results exhibited that V-set domain containing T cell activation inhibitor 1 was overexpressed in various tumor types. As an independent risk factor for the prognosis of 12 different cancer types, V-set domain containing T cell activation inhibitor 1 expression had a connection with survival status. Additionally, it is advantageous in 15 different cancer types for diagnosis. Meanwhile, in 10 and 7 cancer types, the expression of V-set domain containing T cell activation inhibitor 1 was distinctly correlated to tumor mutational burden and microsatellite instability. And the close connection of V-set domain containing T cell activation inhibitor 1 with immune cell infiltration was considered, especially T cells cluster of differentiation 8+, T cells cluster of differentiation 4+, neutrophils, myeloid dendritic cells, macrophages and B cells within most types of cancer. The implication of V-set domain containing T cell activation inhibitor 1 showed the valuable prognostic potentiality in multiple cancers, and it may function as an immunotherapy target in multiple malignant tumors according to the impact on tumorigenesis and tumor immunity.